Crohn’s Disease Costs Could Be Lowered By Monitoring Biotherapeutic Treatments

Crohn’s Disease Costs Could Be Lowered By Monitoring Biotherapeutic Treatments
THERADIAG is a company that specializes in theranostics — a new therapeutic paradigm capable of diagnosis, drug delivery and monitoring therapeutic response. The company recently announced that anti-TNF monitoring, together with anti-TNF antibodies’ treatment in Crohn’s disease patients administered biotherapy, has a major impact on final costs of treatment, saving up to 25%, according to a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *